Saikosaponin D: A potential therapeutic drug for osteoarthritis. (7th July 2020)

• Record Type: Journal Article
• Authors: Jiang, Junsong; Meng, Yanfeng; Hu, Songfeng; Botchway, Benson O.A.; Zhang, Yong; Liu, Xuehong
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 14:Number 8(2020)
• Page Start: 1175
• Page End: 1184
• Publication Date: 2020-07-07
• Subjects: apoptosis -- autophagy -- chondrocyte -- inflammation -- osteoarthritis -- PI3k/Akt/mTOR signaling pathway -- Saikosaponin; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.3090
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Osteoarthritis is a degenerative joint disease. Currently, no effective therapeutic exists for osteoarthritis in the clinic setting. Inflammatory response and autophagy are key players in the occurrence and prognosis of osteoarthritis. In recent years, the regulation of inflammation and autophagy signal pathway has been touted as a potential treatment course for osteoarthritis. Saikosaponin D has anti‐inflammatory and induces autophagy effects via inhibiting the nuclear transcription factor‐κB, mTOR signaling pathways. Here in the report, we analyze and summarize recent evidences pertaining to the relationship between Saikosaponin and osteoarthritis. Published studies were scoured for in research databases, such as PubMed and Scopus with the keywords Saikosaponin and osteoarthritis. Phosphatidylinositol 3‐kinase (PI3k)/Akt/mTOR signaling pathway is an important autophagy modulator, and can regulate chondrocytic autophagy, inflammation, and apoptosis. Saikosaponin D alleviates inflammation and regulates autophagy by inhibiting the PI3k/Akt/mTOR signaling pathway. Saikosaponin D could be a potential therapeutic drug for osteoarthritis.